Long-term efficacy and safety of viltolarsen in the treatment of Duchenne muscular dystrophy

被引：0

作者：

Clemens, P. ^{[1
]}

Connolly, A. ^{[2
]}

Harper, A. ^{[3
]}

Mah, J. ^{[4
]}

McDonald, C. ^{[5
]}

Rao, V. ^{[6
]}

Smith, E. ^{[7
]}

Zaidman, C. ^{[8
]}

Nakagawa, T. ^{[9
]}

Hoffman, E. ^{[10
]}

机构：

[1] Univ Pittsburgh, Pittsburgh, PA USA

[2] Nationwide Childrens Hosp, Columbus, OH USA

[3] Childrens Hosp Richmond, Richmond, VA USA

[4] Univ Calgary, Calgary, AB, Canada

[5] Univ Calif Davis, Sacramento, CA 95817 USA

[6] Lurie Childrens Hosp Chicago, Chicago, IL USA

[7] Duke Univ, Med Ctr, Durham, NC USA

[8] Washington Univ, St Louis, MO 63110 USA

[9] NS Pharma, Paramus, NJ USA

[10] SUNY Binghamton, Sch Pharm, Binghamton, NY USA

来源：

NEUROMUSCULAR DISORDERS | 2021年 / 31卷

关键词：

D O I：

10.1016/j.nmd.2021.07.165

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP.140

引用

页码：S91 / S91

页数：1

共 50 条

[21] Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade
Biggar, WD
Harris, VA
Eliasoph, L
Alman, B
NEUROMUSCULAR DISORDERS, 2006, 16 (04) : 249 - 255
[22] Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment
Joanna Yuet-ling Tung
Tsz-ping Lam
Sophelia Hoi-shan Chan
Journal of Bone and Mineral Metabolism, 2021, 39 : 606 - 611
[23] The evaluation of bone age in patients with Duchenne muscular dystrophy on long-term glucocorticoid treatment
Annexstad, E.
Westvik, J.
Myhre, A.
Bollerslev, I.
Holm, I.
Rasmussen, M.
NEUROMUSCULAR DISORDERS, 2015, 25 : S197 - S197
[24] Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment
Tung, Joanna Yuet-Ling
Lam, Tsz-Ping
Chan, Sophelia Hoi-Shan
JOURNAL OF BONE AND MINERAL METABOLISM, 2021, 39 (04) : 606 - 611
[25] LONG-TERM EFFICACY OF ATALUREN FOR THE TREATMENT OF NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY: OBSERVATIONAL DATA FROM THE STRIDE REGISTRY
Delage, Abdallah
Buccella, Filippo
Desguerre, Isabelle
Muntoni, Francesco
Nascimento, Andres
Tulinius, Mar
Kristensen, Allan
Santos, Claudio
Able, Rich
Trifillis, Panayiota
Zhang, Olivia
Mercuri, Eugenio
MUSCLE & NERVE, 2019, 60 : S5 - S5
[26] Design of a Phase 3 Trial to Evaluate the Long-Term Efficacy and Safety of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
Trifillis, Panayiota
Riebling, Peter
O'Mara, Edward
Luo, Xiaohui
McIntosh, Joseph
NEUROLOGY, 2018, 90
[27] Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
Goemans, Nathalie M.
Tulinius, Mar
van den Hauwe, Marleen
Kroksmark, Anna-Karin
Buyse, Gunnar
Wilson, Rosamund J.
van Deutekom, Judith C.
de Kimpe, Sjef J.
Lourbakos, Afrodite
Campion, Giles
PLOS ONE, 2016, 11 (09):
[28] DESIGN OF A PHASE 3 TRIAL TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY
Trifillis, Panayiota
Schilling, Traci
O'Mara, Edward
McIntosh, Joseph
MUSCLE & NERVE, 2018, 58 : S59 - S59
[29] Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutation Duchenne muscular dystrophy
Riebling, P.
O'Mara, E.
Luo, X.
Trifillis, P.
Ong, T.
NEUROMUSCULAR DISORDERS, 2017, 27 : S218 - S218
[30] Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan
Goto, Masahide
Komaki, Hirofumi
Takeshita, Eri
Abe, Yoshiki
Ishiyama, Akihiko
Sugai, Kenji
Sasaki, Masayuki
Goto, Yu-ichi
Nonaka, Ikuya
BRAIN & DEVELOPMENT, 2016, 38 (09): : 785 - 791

← 1 2 3 4 5 →